Anbio Biotechnology (NNNN): Cash & Equivalents
$7.77M
As of 2025-12-31
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.77M | -34.0% | 2026-04-07, Balance as of period end |
| 2024-12-31 | $11.76M | +21.4% | 2026-04-07, Balance as of period end |
| 2023-12-31 | $9.69M | n/a | 2025-04-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Anbio Biotechnology (NNNN) | 2025-12-31 | $7.77M | -34.0% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $1.75M | -0.8% |
| Biomerica Inc (BMRA) | 2026-05-31 | $1.31M | -45.5% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $11.58M | +34.1% |
| Immucell Corp (ICCC) | 2025-12-31 | $3.81M | +1.3% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $5.91M | +59.4% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $1.12M | -65.8% |
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $28.87M | +1.8% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $155.46M | -17.8% |
Compare NNNN, AWHL, BMRA, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗